Sienna biopharmaceuticals, inc. (SNNA)
Income statement / Yearly
Dec'18Dec'17Dec'16Dec'15
Operating expenses:
Research and development

51,592

30,484

10,993

2,407

General and administrative

24,906

18,087

9,696

8,703

Total operating expenses

76,498

48,571

20,689

11,110

Loss from operations

-76,498

-48,571

-20,689

-11,110

Other income (expense), net

3,027

-2,264

-473

-184

Net loss before taxes

-73,471

-50,835

-21,162

-11,294

Income tax benefit

-

-290

-

-

Net loss

-73,471

-50,545

-21,162

-11,294

Other comprehensive income (loss):
Cumulative translation adjustment

-2,171

5,736

-366

-

Comprehensive loss

-75,642

-44,809

-21,528

-11,294

Per share information:
Net loss, basic and diluted

-3.59

-5.19

-12.49

-6.61

Weighted average shares outstanding, basic and diluted

20,450

9,735

1,694

1,709